Implantation of normal preoptic area (POA) tissue into the third ventricle of adult hypogonadal (HPG) mice provides a source of GnRH neurons that innervate the host median eminence and stimulate reproductive development in the sterile mutants. To further evaluate graft-host integration, the effects of N-methyl-D,L-aspartic acid (NMA) and opiate antagonists on LH secretion in HPG mice with POA transplants (HPG/POA) were tested. NMA challenges significantly stimulated LH secretion in 10 of 11 HPG/ POA females. Only 5 of 12 HPG/POA males responded to the same treatment. Administration of the opiate antagonists naloxone or naloxone methiodide was ineffective in stimulating LH release in any mice, but opiate antagonist pretreatment significantly potentiated the LH secretory response to NMA in female, but not male, HPG/POA mice. A potential anatomical substrate for this facilitation may be the O-endorphin-immunoreactive innervation of the POA grafts in all HPG/POA brains examined. P-Endorphin fibers were also present in the median eminence in the vicinity of GnRH outgrowth from the grafts. However, similar innervation patterns in HPG/POA males that did not respond to opioid antagonism suggests that this is not sufficient.
INTRODUCTION
Because of an autosomal recessive mutation in the GnRH gene [1] , hypogonadal (HPG) mice are unable to synthesize GnRH and are infertile [2] . Hypogonadism in the adult HPG mouse can be reversed by implantation of normal fetal or neonatal preoptic area (POA) tissue into the third ventricle [3, 41. Transplanted GnRH neurons within POA brain grafts have axons that selectively innervate the host median eminence [5, 6] , where GnRH stimulates pulsatile LH secretion and reproductive development in both male [7] and female [8] HPG mice with POA brain grafts (HPG/POA). Female HPG/POA enter a state of continuous vaginal estrus, ovulate reflexively after mating, and can have successful pregnancies [4, 9] . Some females may then begin to ovulate spontaneously [10] , implying a plasticity of the hypothalamic-pituitary-ovarian axis.
Pharmacological and anatomical studies have revealed that GnRH neurons are influenced by numerous neurotransmitter and peptidergic signals [11, 12] . Saitoh et al. [13] reported that the excitatory amino acid analog, N-methyl-D,L-aspartic acid (NMA), rapidly stimulated LH release in normal male and female mice, as has been described in other species [14] [15] [16] [17] [18] . Female HPG/POA also had significant plasma LH elevations following NMA, but most male HPG/POA, whether intact or castrated, failed to respond [13] . This was despite robust gonadal development and graftderived GnRH fiber innervation of the host median eminence in both sexes. NMA is believed to act via a hypothalamic mechanism to stimulate GnRH release, since NMA does not elicit LH release from the pituitary in vitro [15, 19] , and a GnRH antagonist can block NMA-stimulated LH release [16] .
Along with excitatory amino acids, endogenous opioid peptides are also involved in the regulation of LH release. Although the opiate antagonist naloxone (NAL) increases LH secretion in many species, including gonadally intact male [20] and female [21] rats, it fails to do so in male [22] or female (unpublished results) mice. However, opiate antagonists significantly potentiated NMA-induced LH release in young adult male mice [22] , suggesting that NMA triggers the release of inhibitory endogenous opioid peptides.
The purpose of the present study was to evaluate the possible modulation of NMA-induced LH secretion that may be the basis for the apparently sexually dimorphic response in male and female HPG/POA mice. We first determined whether opioid modulation of NMA-induced LH secretion is present in HPG/POA mice. We hypothesized that endogenous opioid inhibition may be one mechanism involved in the relative failure of male HPG/POA to respond to NMA. Both male and female HPG/POA mice were challenged with opiate antagonists and NMA. Second, as gonadal hormone secretion is an obvious difference between male and female animals, we tested whether estrogen priming would facilitate the ability of male HPG/POA to respond to NMA challenges.
MATERIALS AND METHODS

Animals
HPG mice were offspring of F1 hybrids derived from C3H/HeH x 101/H. Mice were housed in a 14L:10D (lightsout, 1500 h) schedule with food and water available ad libitum. HPG mice were at least 3 mo old at the time of graft surgery (see Results for details). Intraventricular grafts of POA tissue were derived from normal fetuses (El5 or later) or day-of-birth neonates from the same colony, as previously described [23] . Briefly, the POA segment was dissected from the donor ventral forebrain and placed in a drop of sterile saline prior to implantation. HPG hosts were anesthetized with chloral hydrate (360 mg/kg, i.p.) and placed in a Kopf stereotaxic apparatus (David Kopf Instruments, Tujunga, CA) fitted with a mouse adaptor. Tissue was implanted with a 20-gauge needle into the anterior third ventricle of HPG hosts. With the skull level between lambda and bregma, stereotaxic coordinates were -1.0 mm posterior from bregma at the midline, and -5.2 mm from the surface of the brain [24] . Animals were allowed to recover and were tested (see Experimental Design) at least 2 mo after graft surgery. Daily vaginal lavages confirmed that females entered persistent estrus following POA implantation. All procedures and animal care were approved by the Mount Sinai School of Medicine Institutional Animal Care and Use Committee.
Experimental Design
Evaluation of opioid modulation of NMA action in HPG/ POA mice. The action of NMA alone, opiate antagonists alone, and opiate antagonists combined with NMA on LH release in male and female HPG/POA mice was assessed. NAL methiodide (NALMI), a quaternary derivative of NAL that remains outside of the blood-brain barrier [25] was used in addition to NAL. Other studies employing quaternary derivatives of NAL have demonstrated their effectiveness at eliciting LH release [26] or antagonizing morphine inhibition of LH release [27] in the rat, suggesting that opioid modulation of GnRH release may occur at a circumventricular location, such as the organum vasculosum of the lamina terminalis or the median eminence. Blood samples were collected at -10, 0, +10, +20, +80 +90, +100, +120, +130, and +140 min. Each mouse received two NMA challenges 2 h apart immediately after the 0 and +120 blood samples, and NAL, NALMI, or saline solution (SAL) were administered after the +80 blood sample and again immediately before the second NMA challenge. Each mouse received NAL, NALMI and SAL treatments on separate consecutive days, and treatment order was randomized. All drugs were administered i.v. through the cannula and always after a blood sample was drawn. NMA (Sigma Chemical Co., St. Louis, MO) was administered at a dose of 20 mg/4.0 ml saline/ kg body weight. NAL (Sigma Chemical Co.) and NALMI (Research Biochemicals Inc., Natick, MA) were administered at a dose of 3 mg/2.0 ml saline/kg body weight. SAL was administered as 2.0 ml/kg body weight.
Assessment of estrogen modulation of NMA responsivity in HPG/POA male mice. The effect of estrogen treatment on the HPG/POA male's ability to respond to NMA was evaluated in four groups of mice. First, HPG/POA (n = 5) remained gonadally intact throughout the experiment. Two other groups (n = 5/group) were castrated prior to graft implantation, and simultaneously received an s.c. capsule containing 17{3-estradiol (E 2 ) or sesame oil (SO). Similar E 2 and SO capsules were used to prime normal and HPG/POA ovariectomized female mice in our previous studies with NMA challenges 13] . Capsules were made from 10 mm of silastic tubing (i.d., 0.0102 cm; o.d., 0.0216 cm; Dow-Corning, Midland, MI) filled with SO or 100 [xg E 2 /ml SO, and the ends were sealed with silastic adhesive. These capsules were replaced every 2-3 wk under isoflurane (Anaquest, Madison, WI) anesthesia, such that at the time of testing capsules had been in place for 2-3 wk. The fourth group (n = 8) comprised male HPG/POA that were castrated and given an E 2 capsule 1 wk prior to NMA testing. The males in this group and in the following experiment were chosen according to the criterion that they had attained testicular weights greater than 50 mg after graft surgery, to assure notable graft efficacy. Repeated NMA challenges were used to fully assess the action of NMA on LH release. Blood samples were collected at -10, 0, +10, and +20 min relative to each of six NMA challenges. NMA was administered immediately following the 0 blood samples, at 1000 h, 1200 h, and 1400 h on two consecutive days.
Determination of estrogen modulation of pituitary responsivity in HPG/POA males. Since estrogen may act at the level of both the brain and the pituitary, we determined whether estrogen priming affected pituitary sensitivity to GnRH. Male HPG/POA mice were castrated and received an s.c. capsule containing either E2 (n = 7) or SO (n = 7) one week before testing. On the first day of testing, all mice were challenged with 1 ng GnRH/0.1 ml saline at 1000 h, and 100 ng GnRH/0.1 ml saline at 1200 h. On the next day, mice were challenged with NMA at 1000 h, 1200 h, and 1400 h. Blood samples were collected at -10, 0, +10, +20, and +30 min relative to each GnRH or NMA challenge.
Intracardial Cannulation
Each mouse was fitted with an intracardial cannula under chloral hydrate anesthesia (360 mg/kg, i.p.) during morning hours. The intracardial cannulation procedure has been described previously [8] and was adapted from Weeks [28] . After surgery, each mouse was placed in a clean cage and returned awake to the colony room prior to lights-out at 1500 h.
Blood Sampling
Blood sampling was performed in recovered animals, beginning on the morning after surgery. At the time of the experiment, a 1-cc syringe filled with 3 U heparin/ml bacteriostatic saline was attached to the cannula and then suspended above each cage, leaving the mouse completely unrestrained. Food and water were supplied. Blood samples (0.1 ml) were collected from awake and freely behaving mice in their home cages at 10-min intervals before and after drug challenges. After centrifugation, plasma fractions (60 il) were flash-frozen in an ethanol and dry ice bath and stored at -20°C until RIA. Throughout an experiment, blood cells from samples were resuspended in steroid-free [29] human serum albumin (5%, 60 xl; Armour Pharmaceutical Co., Kankakee, IL) and introduced back into the host via the cannula immediately after the next sample was withdrawn or after a drug administration.
Perfusion and Gonadal Collection
Animals were killed after all testing with an overdose of chloral hydrate. All HPG/POA that were castrated at the time of POA implantation along with selected HPG/POA from the other groups were deeply anesthetized with chloral hydrate and perfused through the heart with saline and Zamboni's fixative. The brain was removed, placed in Zamboni's fixative for 1-4 days, and stored in cryoprotectant [30] at -20 0 C until immunocytochemistry was performed. Gonadal tissue was removed and weighed after the animals were killed.
Immunocytochemical Methods
Brains were sectioned on a vibratome at 40 lm. Immunocytochemical detection of GnRH was carried out with the LR1 antiserum (courtesy of R. Benoit) at a 1:20 000 dilution and of [3-endorphin with antibody [31, 32] in a 1:4000 dilution. A commercial biotinylated secondary antibody (Vector Labs., Burlingame, CA), and an avidin-biotin-horse radish peroxidase complex (Vector Labs.) using a nickel intensification of 3,3' diaminobenzidine (20 mg DAB, 80 mg Ni(NH 4 ) 2 SO 4 , 100 ml 0.05 M TRIS, pH 7.6) was used as the chromogen. Sections were dehydrated, cleared, coverslipped, and photographed.
RA for LH
RIA of LH was performed with the kit for rat LH (provided by the NIDDK through the National Hormone and Pituitary Program), with rat (r) LH RP-2 used as a reference standard. Iodinated rLH (Hazleton, Vienna, VA) was used as a tracer. Plasma samples (25 RlI) were assayed in duplicate. All samples from a given subject were in the same assay. Each assay was centrifuged in its entirety, and a standard curve and plasma pool were run in every assay. The mean intraassay coefficient of variation, calculated on a mouse plasma pool (n = 7-10), was 9.2%; the mean interassay variation, calculated from values obtained by assaying this pool in each assay, was 9.9%. The limit of detection ranged from 0.2 to 0.5 ng/ml.
Statistics
All values obtained were expressed as the mean SE. Determination of a significant endogenous LH pulse or LH increase following a drug challenge in an individual mouse was based on the following criteria: 1) an initial elevation of plasma LH greater than 20% of the previous LH value, and 2) a coefficient of variation of the LH values encompassing the peak value that was greater than twice the intraassay coefficient of variation [13] . For each sex, two-way analysis of variance (ANOVA) with repeated measures on both factors was used to assess differences in LH secretion between and within groups. The first factor was treatment (NAL, NALMI, or SAL). The second factor was time of blood sampling within each treatment. When p < 0.05 for ANOVA, post hoc comparisons between mean values at each time point were made with Tukey's HSD. Differences were considered significant ifp < 0.05.
To determine whether estrogen treatment affected the propensity of HPG/POA males to have significant LH secretion after NMA challenges, the percentage of subjects in each group with significant increases in LH was determined for each NMA challenge. Significant differences between groups were evaluated with a Kruskal-Wallis nonparametric ANOVA. When p < 0.05, comparisons between individual groups were assessed with Mann-Whitney U-tests.
RESULTS
Effect of NMA and Opiate Antagonists on LH Release in Female HPG/POA
Female HPG/POA mice (n = 11) were tested 3-7 mo after graft surgery and were 7-11 mo old at the time of testing. All but one had been paired with a fertile normal male, and two had borne litters prior to testing. . In HPG/POA females there were significant differences in the main effects and in the interaction between the main effects. Specifically, there was an overall significant difference for the effect of treatment (p < 0.04; Fig. 1 ), for the time of sampling (p < 0.0001), and for the interaction between treatment and time of sampling (p < 0.007). There was significant LH secretion (p < 0.01, +10 vs. 0 time point) in reaction to NMA alone but not to either opiate antagonist when administered alone. Pretreatment with either NAL or NALMI resulted in 1) a significantly enhanced LH secretory response to NMA in the presence of NAL and NALMI pretreatment (+130 and +140 vs. +10 and +20, respectively) and 2) a significantly enhanced LH secretory response to NMA at + 130 and + 140 with NAL and NALMI pretreatment as compared to the same time points after SAL pretreatment, respectively. Individually, 10 of the 11 HPG/POA females responded to at least one of the first NMA challenges. There was no significant difference in LH values in response to the first vs. second NMA challenge with SAL pretreatment.
Effect of NMA and Opiate Antagonists on LH Release in Male HPG/POA
Male HPG/POA mice (n = 12) in this experiment were tested 3-12 mo after graft surgery and were 7-16 mo old at testing. Testes weights were 68.6 + 10.9 mg (vs. same aged untreated HPG: 6.4 + 1.2 mg; normal: 213.2 + 6.4 mg [33] ), and seminal vesicle weights were 95.8 + 20.3 mg (vs. HPG: 2.1 + 0.5 mg; normal: 235.1 + 13.0 [33] ).
In HPG/POA males, the effect of treatment was not significant (p = 0.74; Fig. 2 ), nor was the interaction between treatment and time of sampling (p > 0.94). However, effect of time of sampling was significant (p < 0.03). Post hoc tests on this effect indicated significant responses after NMA challenge at + 10 in the SAL and NALMI treatment sampling, and at + 130 in all three treatments. In no case were there significant differences in responses to the first vs. second challenges. These findings were due to significant LH secretion in just five of the 12 HPG/POA males tested. Of interest is that among the five NMA responders were the two oldest HPG/POA males (W21 and W22), aged 16 mo and bearing their grafts for 1 yr. W21 responded with significant LH release to all challenges, while W22 responded significantly to two of the three NMA challenges and to the NMA challenges combined with NAL and NALMI. In contrast, among those that never responded to NMA despite their robust gonadal development were the three youngest males (W16, W32, and W33). These mice were 7 mo old at testing and had borne their grafts for 3 mo. Three males (T04, T13, and W21) had small but significant elevations in plasma LH after NAL alone, and T04 and W21 also had sig- Effect of NAL (3 mg/kg), NALMI (3 mg/kg), or SAL, administered alone and combined with NMA (20 mg/kg) on plasma LH levels in female HPG/POA. Each mouse (n = 11) received two NMA challenges, immediately after the 0 and +120 blood samples on 3 consecutive days. Mice were pretreated with NAL (top), NALMI (middle), or SAL (bottom), administered after the +80 blood sample and again immediately before the second NMA challenge. The response to NMA alone (p < 0.01: +10 min vs. the 0 time point) but not to NAL, NALMI, or SAL alone was significant. Pretreatment with either NAL or NALMI resulted in 1) a significantly enhanced LH secretory response to NMA at the +130 and +140 time points as compared to the +10 and +20 time points within the treatment, respectively; and 2) a significantly enhanced LH secretory response to NMA at the +130 and +140 time points as compared to the same time points with SAL pretreatment, respectively. There was no significant difference in LH values in response to the first vs second NMA challenge with SAL pretreatment. * p < 0.05; ' p < 0.01; applicable to both comparisons.
nificant increases in LH secretion following NALMI alone. However, since all three mice had similar changes in plasma LH after SAL alone, it is not clear whether these increases in LH secretion represented true responses to the drugs or ongoing endogenous LH pulsatility. timepoints during the SAL and NALMI treatments and at +130 in the NAL treatment sampling. There were no significant differences between the first and second NMA challenges in any treatment.
Immunocytochemistry for P-Endorphin and GnRH
Because opiate-antagonist-induced potentiation of the NMA-stimulated LH response was seen in female but not in male HPG/POA, immunocytochemistry for j3-endorphin was performed on representative female (n = 7) and male (n = 3) HPG/POA brains to provide preliminary information on a possible anatomical substrate. However, there was at least modest B-endorphin innervation of the graft in each of these brains, whether male or female. No P-endorphin cell bodies were present in any grafts. Some brains (both male and female) had robust innervation by P-endorphin-immunoreactive fibers throughout the dorsal-ventral extent of the graft. Fibers were present in areas where the graft appeared to merge with the host brain (Fig. 3) , in one case in a small bridge of tissue between graft and host (Fig. 4) . A few grafts had large areas completely devoid of immunoreactive fibers (Fig. 5) . Occasionally fibers were seen at the lateral boundary of the graft along the third ventricle. In every case, P-endorphin cell bodies were contained entirely within the host brain and were concentrated in the medial basal hypothalamus (Fig. 5) .
To confirm the long-term survival of GnRH neurons within the grafts, the brains of the two oldest HPG/POA males (W22 and W21) were processed for immunocytochemistry for GnRH. The viability of their grafted GnRH neurons was suggested by their responsivity to multiple NMA challenges. GnRH immunoreactive neurons and fiber innervation of the median eminence were detected in both grafts (Fig. 6 ). GnRH fibers also innervated the median eminence (Fig. 7 ) in all three of the youngest males studied (W16, W32, W33), which had failed to respond to NMA. Immunocytochemistry for 13-endorphin was also performed on these three brains, and -endorphin fibers were present in all of the grafts (Fig. 8 ) and ranged from sparse to abundant (Fig. 8) . When doublelabel experiments were carried out, 13-endorphin fibers were occasionally observed in close proximity to GnRH cell bodies or axons within the grafts (data not shown). However, double-label ultrastructural studies are necessary to determine whether any synaptic interactions take place between these two peptidergic components. 
Effect of E 2 Treatment on Male HPG/POA Responsivity to NMA Challenges
All HPG mice in this and the subsequent experiment were 3-5 mo old at time of graft surgery and received NMA challenges 2 mo later. Intact HPG/POA had robust testicular and seminal vesicle development (Table 1) . GnRH immunocytochemistry revealed GnRH neurons within the POA graft and fiber innervation of the host median eminence in all of these brains. Corresponding plasma LH data (Fig. 9A ) and GnRH immunocytochemistry (Fig. 10A ) are shown for a representative intact HPG/POA (Z24). Despite these functional POA implants, just two intact HPG/POA males responded to one of six NMA challenges with significantly elevated plasma LH levels (Table 1) . Similarly, NMA chal- Plasma LH values before and after six separate NMA challenges in representative HPG/POA male mice subjected to various E 2 treatments. Four blood samples were collected at 10-min intervals starting at times shown, on 2 consecutive days. NMA was administered after second blood sample. A) Intact HPG/POA Z24. No significant plasma LH increases followed any of the six NMA challenges. B) Castrated male HPG/POA treated with SO at time of POA implantation (Z33). Note spontaneous LH pulse detected at 1210 h on Day 1, just prior to NMA challenge. *This mouse responded to last NMA challenge with modest but significant increase in plasma LH levels at 20 min after the challenge. C) Castrated male HPG/POA treated with E 2 at time of POA implantation (Z21). *This mouse responded to all three NMA challenges on second day of testing with significant elevations in plasma LH levels. D) Castrated male HPG/POA treated with E 2 at 1 wk prior to testing (BB12). *This mouse responded to all six NMA challenges with extreme elevations in plasma LH levels. Note scaling change for Y axis.
lenges elicited LH release in only one SO-treated HPG/POA castrated prior to graft implantation. Representative plasma LH data (Fig. 9B ) and GnRH immunocytochemistry (Fig. 10B) are shown for an SO-treated HPG/POA (Z33). Because the mice that were castrated prior to POA implantation could not be classified as "responders" according to the criteria of gonadal development, immunocytochemistry for GnRH was necessary to confirm graft survival and GnRH fiber innervation of the host median eminence. One animal in this group (Z04) had no detectable GnRH immunoreactivity.
A significantly greater proportion of individuals in the E 2 -treated groups responded to NMA challenges (p -0.025 vs. intact or SO; Table 1 ). Four of five E 2 -treated HPG/POA castrated prior to graft implantation responded to at least two of six NMA challenges with significant elevations in plasma LH. The brains of these four NMA responders had GnRH neurons within the POA transplant and fiber innervation of the host median eminence. Representative GnRH immunocytochemistry on a brain section of one of these males (Z21) is shown in Figure 10C , with corresponding plasma LH data in Figure 9C . The brain of the non-NMAresponder (Zll1) had very modest fiber innervation of the host median eminence.
Six of eight HPG/POA castrated and treated with E2 at 1 wk prior to testing responded to at least one NMA challenge, and three responded to all six NMA challenges (Table 1). One animal in this group (BB12) had exaggerated LH values after NMA challenges (Fig. 9D) , and GnRH immunoreactive cell bodies were located just dorsal to the host median eminence (Fig. 10D ). Castrated + E 2 -treated prior to graft implantation: 
Pituitary Responsivity to GnRH
HPG/POA males had similar testicular development prior to castration in the SO-treated (n = 7: 109.8 + 10.5 mg) and E-treated (n = 7: 95.6 -16.6) groups. Both low (1 ng) and high (100 ng) doses of GnRH significantly stimulated LH release (Fig. 11) . There was no significant difference between the groups (p = 0.61, ANOVA). When these animals received NMA challenges on the next day, a significantly greater proportion of the E 2 -treated castrates responded (p < 0.04, data not shown), replicating the previous observations.
DISCUSSION
We propose that NMA stimulates both excitatory and inhibitory afferents to the GnRH neuronal system, and that one of the effects of NMA is the activation of inhibitory opioidergic afferents to the GnRH neuronal system. This is in addition to a possibly direct action on GnRH neurons [34] , which may account for our finding of NMA-stimulated LH secretion in HPG female mice with implants of GT1-7 cells in the hypothalamus [35] . As previously reported [13] , female HPG/POA mice here responded to NMA with significant LH secretion, while there was a general deficit in the ability of untreated male HPG/POA with robust gonadal development to respond to NMA. Significant NMA effects, with or without pretreatments, were due to responses in a minority of the male mice. Although opioid blockade alone had no effect on LH secretion, female HPG/POA had significantly greater LH secretory responses to NMA when an opiate antagonist was present, similar to our previous findings in normal mice [22] . In contrast, the relative failure of intact HPG/POA males to react to NMA does not appear to be due to opioid inhibition of GnRH release. Such males responded only occasionally to NMA challenge with LH secretion, whether or not endogenous opioids were blocked by antagonists. However, either short-(1 wk) or long-term (2 mo) E 2 treatment potentiated the ability of HPG/POA males to respond to NMA.
While treatment of HPG/POA males with low doses of E 2 eliminated the apparent sex difference in responsivity, the question remains why such a dimorphism is not seen in normal males and females. One possibility is that in normal males, aromatization of testicular androgens within the brain provides sufficient estradiol to enable the response to NMA. We hypothesize that the amount of testosterone secreted from the stimulated testes in HPG/POA males does not reach high enough levels to provide substrate for aromatization to sufficient estrogen. We previously found that HPG/POA males with significant gonadal development nevertheless required exogenous testosterone propionate to exhibit male sexual behavior [36] . It is known that aromatization of androgens plays an important role in male development. Copulatory behavior is stimulated by aromatizable androgens [37] , suppressed by antiestrogens [38] , and diminished by inhibitors of estrogen synthesis [39] . As aromatases are induced by androgens [40] , there may be a delayed induction in the hypothalami of HPG mice after graft surgery. Consistent with this is the observation that among the few male HPG/POA responders to NMA were two males with 12-mo-old grafts. Studies are planned to evaluate the relevance of these findings to the development of responsivity in normal male mice.
The finding that 1-endorphin-immunoreactive cell bodies were apparent only within the host brain supports the hypothesis that 1-endorphin-immunoreactive fibers seen in the grafts originated from the host. Such fibers may be a possible anatomical substrate for opiate-antagonist-induced elevations in the LH response to an NMA challenge. Another site for this interaction may be at the borders of the median eminence, where 1-endorphin fibers were present in the region consistently innervated by graft-derived GnRH fibers ( [3] [4] [5] 41, 42] , this study). The ability of NALMI, which does not cross the blood-brain barrier, to enhance NMAstimulated LH secretion in both normal mice and HPG/POA females is consistent with opioidergic modulation of LH release occurring at or in close proximity to a circumventricular location, such as the median eminence. Ultrastructural immunocytochemistry is necessary to confirm whether there is any synaptic connectivity between host-derived 13-endorphin fibers and graft-derived GnRH elements either in the graft or in the median eminence.
We have previously shown that NMA induces c-fos protein expression, a marker of neuronal activation, in many neurons including 1-endorphin-containing neurons in the medial basal hypothalamus of the normal mouse [41] . 13-Endorphin-immunoreactive terminals are known to synapse directly on GnRH cell bodies in male [31] and female [32] rats, with a sexually dimorphic pattern [32] . In the present study, -endorphin-immunoreactive fibers were evident in the graft and in areas of graft-host fusion (Figs. 3 and 4), whereas 13-endorphin-containing cell bodies were entirely within host hypothalamic tissue adjacent to the graft (Fig. 5) . The absence of f3-endorphin-immunoreactive cell bodies in the grafts was not surprising, as the POA tissue is excised rostral to the medial basal hypothalamus, the hypothalamic site of -endorphin neurons in the rodent [43] . The present findings are in agreement with our previous observations of 13-endorphin-and arcuate nucleus-derived innervation of the graft identified with immunocytochemistry and DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate) tracing [42] .
An interesting exception to the relative insensitivity of untreated HPG/POA males to NMA was the response of the two oldest male HPG/POA mice. We had previously shown that older (10-16 mo old) normal male mice were more sensitive than younger males to NMA [22] , and further, that their increased LH secretion was not due to altered pituitary sensitivity. Pretreatment with opioid antagonists did not alter responsivity to NMA in these older normal males. Together, these earlier findings suggested that opioid inhibition is diminished in aging male mice. Possible mechanisms for such a change include alterations in opioid receptors and in synaptic connectivity. Plasticity in neuronal connectivity with aging has been described in normal male rats, with increased synaptic input to GnRH neurons [44] . Similar to older normal male mice, HPG/POA males also lacked opiate-antagonist-induced potentiation of NMA-stimulated LH release. Both GnRH cell survival and pharmacological responses, along with significant gonadal development in these mice, demonstrate that GnRH neurons within a POA graft can survive and function for at least one year following implantation, and may be subject to aging processes of the host.
Facilitation of sensitivity to NMA by E 2 treatment of the HPG/POA males is consistent with the high incidence of NMA responsivity in female HPG/POA. However, in a previous study by Saitoh et al. [13] , ovariectomized female HPG/ POA also responded to a single NMA challenge with significant LH secretion. Thus estrogen is not essential at the time of NMA challenge for female HPG/POA to have significant LH responses. This suggests that estrogen may have an effect on the brain that persists after its removal. Central effects of estrogen include alterations in synaptology in the POA [45] and in the ventromedial [46, 47] and arcuate [48, 49] nucleus of the ovariectomized rat, and alterations in muopioid receptor density in female mice [50] . Future studies will examine whether NMA-stimulated LH release in E 2 -treated HPG/POA males persists after E 2 removal. It will also be of interest to determine whether E 2 treatment facilitates opioid modulation of NMA action in HPG/POA males.
Estrogen is known to selectively accelerate and enhance neuritic proliferation and branching in organotypic cultures of newborn mouse hypothalamus and POA [51, 52] . We have shown that POA grafts are rich in estrogen receptors [53] . However, these effects may be limited to those neurons containing intracellular estrogen receptors, which GnRH neurons lack [54] . In the present study, altered steroid milieu at the time of graft implantation surgery did not obviously alter GnRH fiber outgrowth to the median eminence or GnRH cell survival within the graft. Male HPG/ POA that were castrated and SO-or E 2 -treated prior to graft surgery had grafts containing similar numbers of GnRH neurons that comparably innervated the host median eminence.
In summary, the present studies indicate that transplanted GnRH neurons in HPG/POA mice are regulated at least in part by host afferents. Female HPG/POA had significantly greater responses to NMA when an opiate antagonist was present, demonstrating that endogenous opioids may modulate GnRH neurons within POA brain grafts. Hostderived 83-endorphin is a likely candidate as a regulatory element of the GnRH neuronal system in HPG/POA mice, either through innervation of POA grafts or at the level of GnRH fiber innervation of the median eminence. The wide variety of physiological responses to POA grafts in HPG/ POA may be due to differences in the pattern of afferent innervation to the GnRH neuronal system or the activation of these afferents.
